Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines

Journal of Immunology

Volumn 160, Issue 11, 1998, Pages 5355-5365

  Blazar, Bruce R ^a   Taylor, Patricia A ^a   Panoskaltsis Mortari, Angela ^a   Vallera, Daniel A ^a  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; GRANZYME B; INTERLEUKIN 2 RECEPTOR; PADGEM PROTEIN; RAPAMYCIN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; ENZYME RELEASE; FEMALE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; INHIBITION KINETICS; LETHAL DOSE; LEUKEMOGENESIS; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFUSION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; POLYENES; RADIATION CHIMERA; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SIROLIMUS; T-LYMPHOCYTE SUBSETS; TH1 CELLS; UP-REGULATION;

EID: 0032102935     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Sehgal, S., and H. Baker, C. Vezina. 1975. Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. 28:727.
2. Metcalfe, S., and J. Milner. 1990. Evidence that FK506 and rapamycin block T-cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. Transplantation 51:1318.
3. Dumont, F. J., M. J. Staruch, S. L. Koprak, S. L., M. R. Melino, and N. H. Sigal. 1990. Distinct mechanisms of suppression of murine T-cell activation by the related macrolides FK506 and rapamycin. J. Immunol. 144:251.
4. Bierer, B. E., P. S. Mattila, R. F. Standaert, L. A. Herzenberg, S. J. Burakoff, G. Crabtree, and S. L. Schreiber. 1990. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc. Natl. Acad. Sci. USA 87:9231.
5. Bierer, B. E., P. K. Somers, T. J. Wandless, S. J. Burakoff, and S. L. Schreiber. 1990. Probing immunosuppressant action with a nonnatural immunophilin ligand. Science 250:556.
6. Crum Vander Woude, A., and B. E. Bierer. 1997. Immunosuppression and immunophilin ligands: cyclosporin A, FK506, and rapamycin. In: Graft-vs.-Host Disease. J. L. M. Ferrara, H. J. Deeg, and S. J. Burakoff, eds. Marcel Dekker, New York. p. 111.
7. Abraham, R. T., and G. J. Weiderrecht. 1996. Immunopharmacology of rapamycin. Annu. Rev. Immunol. 14:483.
8. Zheng, X. F., and S. L. Schreiber. 1997. Target of rapamycin proteins and their kinase activities are required for meiosis. Proc. Natl. Acad. Sci. USA 94:3070.
9. Morris, R. E. 1993. Prevention and treatment of allograft rejection in vivo by rapamycin: molecular and cellular mechanisms of action. Ann. NY Acad. Sci. 685:68.
10. Ferraresso, M., R. Ghobrial, S. M. Stepkowski, and B. D. Kahan. 1993. The mechanism of unresponsiveness to allografts induced by rapamycin and rapamycin/cyclosporine treatment in rats. Transplantation 55:888.
11. Murgia, M. G., S. Jordan, and B. D. Kahan. 1996. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int. 49:209.
12. Blazar, B. R., P. A. Taylor, D. C. Snover, S. N. Sehgal, and D. A. Vallera. 1993. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. J. Immunol. 151:5726.
13. Blazar, B. R., P. A. Taylor, A. Panaskoltsis-Mortari, S. Sehgal, and D. A. Vallera. 1996. The in vivo inhibition of cytokine responsiveness and GVHD mortality by rapamycin leads to a clinical-pathological syndrome discrete from that observed with cyclosporin A. Blood 87:4001.
14. Blazar, B. R., P. A. Taylor, S. N. Sehgal, and D. A. Vallera. 1994. Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of fully allogeneic T-cell depleted (TCD) donor marrow. Blood 83:600.
15. Blazar, B. R., P. A. Taylor, S. N. Sehgal, and D. A. Vallera. 1993. Rapamycin prolongs survival of murine recipients of fully allogeneic donor grafts when administered during the graft-versus-host disease process. Ann. NY Acad. Sci. 685:73.
16. + lymphoid engraftment. J. Immunol. 152:1004.
17. Fowler, D. H., K. Kurasawa, R. Smith, M. A. Eckhaus, and R. E. Gress. 1994. Donor CD4-enriched cells of Th2 cylokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 84:3540.
18. + donor T cells fail to induce experimental acute graft-versus-host disease. J. Immunol. 155:585.
19. Krenger, W., K. R. Cooke, J. M. Crawford, S. T. Sonis, R. Simmons, L. Pan, J. Delmonte, Jr., M. Karandikar, and J. L. Ferrara. 1996. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. Transplantation 62:1278.
20. Pan, L., J. Delmonte, Jr., C. K. Jalonen, and J. L. Ferrara. 1995. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 86:4422.
21. Nikolic, B., M. J. Grusby, and M. Sykes. 1997. Th1 and Th2 responses cause distinct clinical GVHD syndromes after fully MHC-mismatched STAT 4 and STAT 6 KO bone marrow transplantation. Blood 90(Suppl. 1):395a.
22. Graubert, T. A., J. H. Russell, and T. J. Ley. 1996. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection, Blood 87:1232.
23. Braun, M. Y., B. Lowin, L. French, H. Acha-Orbea, and J. Tschopp. 1996. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med. 183:657.
24. Baker, M. B., N. H. Altman, E. R. Podack, and R. B. Levy. 1996. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J. Exp. Med. 183:2645.
25. + T cells each can utilize a perforin-deficient pathway to mediate lethal graft-versus-host disease in MHC disparate recipients. Transplantation 64:571.
26. Graubert, T. A., J. F. Dipersio, J. H. Russell, and T. J. Ley. 1997. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J. Clin. Invest. 100:904.
27. Dent, A. L., L. A. Matis, F. Hooshmand, S. M. Widacki, J. A. Bluestone, and S. M. Hedrick. 1990. Self-reactive γδ T cells are eliminated in the thymus. Nature 343:714.
28. + T cells. J. Immunol. 157:3250.
29. + T cell mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J. Immunol. 158:29.
30. Blazar, B. R., P. A. Taylor, A. Panoskaltsis-Mortari, T. A. Barrett, J. A. Bluestone, and D. A. Vallera. 1996. Lethal murine graft-versus-host disease induced by transgenic γ/δ expressing T cells. Blood 87:827.
31. + cells. J. Exp. Med. 180:307.
32. Blazar, B. R., P. A. Taylor, M. B. Boyer, A. Panoskaltsis-Mortari, K. B. Gordon, J. P. Allison, and D. A. Vallera. 1997. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-BMT splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J. Immunol. 159:3460.
33. + T cell immune response to murine myeloid leukemia. Blood 85:2498.
34. + T cell line with potent in vivo graft-versus-leukemia properties. Blood 89:3477.
35. Blazar, B. R., P. A. Taylor, P. S. Linsley, and D. A. Vallera. 1994. In vivo blockade of CD28/CTLA4:B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex (MHC) barrier in mice. Blood 83:3815.
36. Panoskaltsis-Mortari, A., and R. P. Bucy. 1995. In situ hybridization with digoxigenin-labelcd RNA probes: facts and artifacts. BioTechniques 18:300.
37. Bucy, R. P., A. Panoskaltsis-Mortari, G. Q. Huang, J. Li, L. Karr, M. Ross, J. H. Russell, K. M. Murphy, and C. T. Weaver. 1994. Heterogeneity of single cell cytokine gene expression in clonal T cell. J. Exp. Med. 180:1251.
38. Mantel, N. 1966. Evaluation of survival data in two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:163.
39. Sprent, J., and J. F. Miller. 1972. Thoracic duct lymphocytes from nude mice: migratory properties and life-span. Ear. J. Immunol. 2:384.
40. Sprent, J., and J. F. Miller. 1976. Effect of recent antigen priming on adoptive immune responses. III. Antigen-induced selective recruitment of subsets of recirculating lymphocytes reactive to H-2 determinants. J. Exp. Med. 143:585.
41. Sprent, J., and H. von Boehmer. 1976. Activation of T lymphocytes to M locus determinants in vivo. I. Quantitaten of T cell proliferation and migration into thoracic duct Lymph. Ear. J. Immunol. 6:352.
42. Pham, C. T., and T. J. Ley. 1997. The role of granzyme B cluster proteases in cell-mediated cytotoxicity. Semin. Immunol. 9:127.
43. Kolb, H. J., J. Mittermuller, C. Clemm, E. Holler, G. Ledederose, G. Brehm, M. Heim, and W. Wilmanns. 1990. Donor leukocyte transfusions for treatment of recurrent chronic myclogenous leukemia in marrow transplant patients. Blood 76:2462.
44. Giralt, S. A., and R. E. Champlin. 1994. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 84:3603.
45. Kolb, H.-J., A. Schattenberg, J. M. Goldman, B. Hertenstein, N. Jacobsen, W. Arcese, P. Ljungman, A. Ferrant, L. Verdonck, D. Niederwieser, F. van Rhee, J. Mittermueller, T. de Witte, E. Holler, and H. Ansari. 1995. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041.
46. Collins, R. H., O. Shpilberg. W. R. Drobyski, D. L. Porter, S. Giralt, R. Champlin, S. A. Goodman, S. N. Wolff, W. Hu, C. Verfaillie, A. List, W. Dalton, N. Ognoskie, A. Chetrit, J. H. Antin, and J. Nemunaitis. 1997. Donor leukocyte infusion in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15:433.
47. Cohen, S. B., S. L. Parry, M. Feldmann, and B. Foxwell. Autocrine and paracrine regulation of human T cell IL-10 production. J. Immunol 158:5596.
48. Boussiotis, V. A., A. Berezovskaya, E. C. Guinan, J. G. Gribben, D. L. Barber, and L. M. Nadler. 1997. In the presence of a T cell receptor (TCR) signal, rapamycin but not cyclosporin-A. inhibits CD28 and IL-2 mediated pathways resulting in the induction of anergy, Blood 90:562a.
49. + T cells tolerized in vivo: employing a model of Ld-specific TCR transgenic mice transplanted with allogenic hearts under the cover of a short-term rapamycin treatment. J. Immunol. 157:4297.
50. Ferraresso, M., L. Tian, R. Ghobrial, S. M. Stepkowski, and B. D. Kahan. 1994. Rapamycin inhibits production of cylotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate long-term survival of heart allografts in rats. J. Immunol. 153:3307.
51. Zheng, X. X., T. B. Strom, and A. W. Steele. 1994. Quantitative comparison of rapamycin and cyclosporine effects on cytokine gene expression studied by reverse transcriptase-competitive polymerase chain reaction. Transplantation 58:87.
52. Wasowska, B., K. J. Wieder, W. W. Hancock, X. X. Zheng, B. Berse, J. Binder, T. B. Strom, and J. W. Kupiec-Weglinski. Cytokine and alloantibody networks in long term cardiac allografts in rat recipients treated with rapamycin. J. Immunol. 156:395.
53. Blazar, B. R., P. A. Taylor, S. Smith, and D. A. Vallera. 1995. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex (MHC) disparate donor grafts. Blood 85:84.
54. Krenger, W., K. Snyder, S. Smith, and J. L. Ferrara. 1994. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation 58:1251.
55. + T cells. J. Exp. Med. 184:19.
56. Groux, H., A. Ogarra, M. Bigler, M. Rouleau, S. Antonenko, J. E. Devries, and M. G. Roncarolo, 1997. A CD4(+)T-cell subset inhibits antigen-specific T-Cell responses and prevents colitis. Nature 389:737.
57. Makrigiannis, A. P., and D. W. Hoskin. 1997. Inhibition of CTL induction by rapamycin: IL-2 rescues granzyme B and perforin expression but only partially restores cytotoxic activity. J. Immunol. 15:4700.
58. Wieder, K. J., W. W. Hancock, G. Schmidbauer, C. L. Corpier, I. Wieder. L. Kobzik, T. B. Strom, and J. W. Kupiec-Weglinski. 1993. Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-γ in rat recipients of cardiac allografts. J. Immunol. 151:1158.
59. + Tel and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J. Immunol. 157:4811.
60. +, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL. Blot. Blood Marrow Transplant. 2:118.